

Erythrocyte membrane fatty acids in hyperlipidemic patients

Hana M. Gashlan*, Ayat M. Shourbaji

Biochemistry Department, King Abdulaziz University, Faculty of Sciences, Jeddah, Saudi Arabia

Correspondence: Hana M. Gashlan, Biochemistry Department, King Abdulaziz University, Faculty of Sciences, Jeddah, Saudi Arabia. Email: hgashlan@kau.edu.sa, ashorbaji@kau.edu.sa

ABSTRACT

Background: Erythrocytes are always exposed to oxidative stress, affecting their membrane lipid composition and function. Impaired fatty acids (FAs) composition of erythrocyte membrane were observed in numerous physiological and chronic diseases. **Objective:** The aim of the current investigation was to find out the changes in the composition of saturated, monounsaturated and polyunsaturated fatty acids in both plasma and erythrocyte membrane in hyperlipidemia patients. **Material and Method:** One hundred subjects were enrolled to the study. They were divided into: healthy control group (n= 30), newly diagnosed hyperlipidemia group, ND, (n=33) and treated hyperlipidemia group, TH, (n=37). RBC membrane FAs were separated, identified and were analyzed using gas-chromatography. **Results:** Significant elevation in almost all detected FAs in RBC membrane were registered. Palmitic and stearic acids were the main contributors in saturated fatty acids (SFAs), while Oleic and lauric acids were the major components of mono-unsaturated fatty acids (MUFAs). From the main contributors to polyunsaturated fatty acids (PUFAs) were linoleic and arachidonic. Levels of MUFAs were higher in ND hyperlipidemia compared to healthy subjects. Same trend was also noted in TH patients compared to control volunteers. Results also demonstrated elevated percent of SFAs and MUFAs and decreased PUFAs percent, from total fatty acids, in hyperlipidemia groups. From total fatty acids the percent of either SFAs or MUFAs was greater than percent of PUFAs. PUFAs n-6 series were elevated in RBC membrane, while n-3 series showed remarkable decreased values in RBC membrane of some patients in ND and TH groups. Decreased saturation index was also obtained in ND and TH patients compared to control subjects. **Conclusion:** patients with hyperlipidemia, either ND or TH, had marked elevation in almost all FAs in plasma and RBC membrane. The percentage of SFAs and MUFAs from total FAs were increased while the percentage of PUFAs was decreased in hyperlipidemia. Increased dietary SFAs might lead to elevated membrane SFAs which in turn will lead to higher levels of MUFAs in ND and TH patients. Saturation index of RBC membrane, which is an indication of membrane fluidity, was decreased in patients' group compared to control. Increased dietary intake and alterations in the metabolism of FAs may be responsible for the observed changes.

Keywords: Red blood cells membrane, saturated fatty acids, unsaturated fatty acids, hyperlipidemia

Introduction

Erythrocyte membrane composed of integral proteins, which are important elements with structural functions. Integral proteins are strongly embedded into the lipid layer, making them harder to be extracted from the membrane. Erythrocyte membrane lipids are composed of 60% of phospholipids bilayer, 30% non-esterified cholesterol and 10% glycolipids^[1].

Numerous studies have shown that cell membrane abnormalities and structural changes of erythrocyte are an etiological factor in many diseases of the circulatory system, e.g. hypertension^[2,3], breast cancer^[4], colorectal cancer^[5] and acute pancreatitis^[6]. Therefore, membrane fluidity is an important physicochemical characteristic of biomembranes and an important factor in regulating membrane microviscosity, cell functions and its rheological behavior.

The fluidity of biological membranes is mainly determined by their lipid composition. Cholesterol plays a role in maintaining the bilayer matrix in an "intermediate fluid state"^[7] by regulating mobility of phospholipid fatty acyl chains. An increase in the amount of cholesterol relative to phospholipid has been shown by a variety of physico-chemical techniques to decrease fluidity in both biological and artificial membranes^[8]. The cholesterol/phospholipid molar ratio is not the only determinant of membrane fluidity; the phospholipid composition^[9-11] and the length and degree of unsaturation of

Access this article online

Website: www.japer.in

E-ISSN: 2249-3379

How to cite this article: Hana M. Gashlan, Ayat M. Shourbaji. Erythrocyte membrane fatty acids in hyperlipidemic patients. *J Adv Pharm Edu Res* 2018;7(4):420-427.

Source of Support: Nil, Conflict of Interest: None declared.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

the phospholipid fatty acyl chains affect fluidity^[9,11]. Lipid-protein interactions within a biological membrane may also modify fluidity and so both the lipid/protein ratio and types of protein present may be important^[12,13].

In hyperlipidemia, damage to the plasma membranes of red blood cells is well known. This may result from a higher concentration of cholesterol in plasma and membranes, changes in protein conformation and peroxidation of polyunsaturated fatty acids. These changes make erythrocytes less plastic, lose the ability to adjust their shape to the vessel diameter and aggregate, and they accelerate the development of atherosclerosis^[14, 15]. In addition, the lipid content is known to vary and a raised in triglycerides levels were found which in turn can alter RBC membrane fluidity. Furthermore, hypercholesterolaemia is associated with increased oxidative stress and inflammatory mediators that can damage RBCs and increase RBC membrane rigidity^[16]. The lipids of the membranes of erythrocytes were labeled with saturated and unsaturated fatty acid. When these erythrocytes were subsequently incubated with hydrogen peroxide, both types of fatty acid were transferred from superficial erythrocyte neutral lipids into phosphatidylethanolamine. However, the unsaturated fatty acids of phosphatidylethanolamine were subsequently altered by hydrogen peroxide, whereas the saturated fatty acids were not. The cumulative effect of these processes was a relative decrease in unsaturated fatty acid and an increase in saturated fatty acid in the phosphatidylethanolamine of the erythrocyte membrane. The net effect of these events represents the operation of repair processes which distort the usual fatty acid composition of erythrocyte membranes in the presence of H₂O₂^[11]. The aim of the current investigation was to find out the changes in the composition of saturated, monounsaturated and polyunsaturated fatty acids in both plasma and erythrocyte membrane in hyperlipidemia patients.

Material and Methods

Subjects and study design:

The present study was approved by Faculty of Medicine, Unit of Biomedical Ethics, King Abdulaziz University Hospital. Newly diagnosed and treated dyslipidemia cases were diagnosed by hospital physicians. The criteria for dyslipidemia were levels of total cholesterol > 5.0 mmol/l, low density lipoprotein > 3.0 mmol/l, triglycerides > 1.77 mmol/l, high density lipoprotein < 1.0 mmol/l^[17].

One hundred subjects (62 females & 38 males) were recorded in this study. Their ages ranged from 35 to 50 years. They were divided into three main groups: Control group (C): included 30 healthy volunteers (22 females and 8 males), not suffering from any diseases that might affect lipid profile or any cardiovascular disease, or taking any medications that are known to affect lipid metabolism. Newly diagnosed hyperlipidemic group (ND): included 33 (21 females and 12 males) newly diagnosed patients (uncontrolled hyperlipidemic patients). Treated hyperlipidemic group (TH): included 37 patients with dyslipidemia (19 females and 18 males). Patients were under treatment for at least 6 months before enrollment in the study.

Methods

Blood sample collection: Three milliliter of blood sample were collected from each subject on EDTA tubes after overnight fasting. RBC's were separated from plasma by centrifugation at 1000×g for 10 min at 4°C. Plasma was aliquoted and stored at -80°C (for a maximum period of 3 months) pending assay. Packed RBC's were stored at 4°C for not more than 3 days till analysis

Materials

- Specific kits purchased from HUMAN GmbH Company (Wiesbaden, Germany) were used for determination of plasma lipid profile including cholesterol, triglycerides, high density lipoprotein and low density lipoprotein.
- Separation and identification of fatty acids from plasma and RBC membrane
 - a. Phosphate buffered saline (PBS), PH 7.4, chloroform (CHCl₃), dichloromethane (CH₂Cl₂), methanol (MeOH), sulfuric acid (H₂SO₄), toluene, glacial acetic acid, potassium hydroxide and n-hexane. All were of analytical grade and were obtained from Sigma-Aldrich (St. Louis, MO, USA).
 - b. Standard esterified fatty acids methyl ester (EFAME) solution mixture containing 37 EFAME (10 mg/ml in CH₂Cl₂,) was purchased from Sigma-Aldrich (St. Louis, MO, USA). EFAME standard mixture batch was labeled to contain the following FA as methyl ester: butyric acid 4% (C4:0), caproic acid 4% (C6:0), caprylic acid 4% (C8:0), capric acid 4% (C10:0), undecanoic acid 2% (C11:0), lauric acid 4% (C12:0), tridecanoic acid 2% (C13:0), myristoleic acid 2% (C14:1), myristic acid 4% (C14:0), cis-10-pentadecanoic acid 2% (C15:1), pentadecanoic acid 2% (C15:0), palmitoleic acid 2% (16:1), palmitic acid 6% (16:0), cis-10-heptadecanoic acid 2% (17:1), heptadecanoic acid 2% (C17:0), stearic acid 4% (C18:0), gamma-linolenic acid 2% (C18:3n6), linoleic acid 2% (C18:2n6c), linolelaidic acid 2% (C18:2n6t), linolenic acid 2% (C18:3n3), oleic acid 4% (C18:1n9c), elaidic acid 2% (C18:1n9t), arachidonic acid 2%(C20:4n6), cis-5,8,11,14,17-eicosapentaenoic acid 2% (C20:5n3), cis-11,14,17-eicosatrienoic acid 2%(C20:3n3), cis-11,14-eicosatrienoic acid 2% (C20:2), cis-8,11,14-eicosatrienoic acid 2%(C20:3n6), cis-11-eicosenoic acid 2% (C20:1), arachidic acid 4% (C20:0), cis-4,7,10,13,16,19-docosahexaenoic acid 2% (C22:6n3), heneicosanoic acid 2% (C21:0), cis-13,16-docosadienoic acid 2% (C22:2), erucic acid 2% (C22:1n9), behenic acid 4% (C22:0) tricosanoic acid 2% (C23:0), nervonic acid 2% (C24:1), and lingoceric acid 4% (C24:0).
 - c. Myristic acid ethyl ester was prepared in lab from Myristic acid (C14:1) (Sigma Aldrich, St Louis, MO, USA) and used as internal standard.
 - d. Nitrogen gas (99.999% purity) was obtained from Abdullah Hashim Company (Abdullah Hashim Industrial Gases and Equipment Company Limited, Saudi Arabia).

Biochemical analysis:

Each separated plasma sample was subjected to quantitative determination of plasma cholesterol, triglycerides, HDL-Cholesterol and LDL-Cholesterol.

Extraction and analysis of fatty acids:

The fatty acids content of RBC's membrane after RBCs washing were extracted and esterified according to the procedure of Folch [18] and Rose [19], this procedure was an optimization and a modification for optimal recover extraction of lipid trans-methylation by Khedr [20]. Fatty acids were analyzed by GC-MS, as methyl ester versus standard EFAME solution

Fatty Acids Naming and Grouping:

Fatty acids naming and grouping was carried out using the established method following [4].

Statistical analysis:

Statistical analysis was performed using SPSS statistical software package (SPSS Inc, USA). Numerical data were expressed as mean value for each parameter \pm it is corresponding standard error. One-way analysis of variance (ANOVA) was carried out to test the significance of difference between groups mean values for each parameter. In case of significant P-value, multiple comparisons using Tukey's HSD (honestly significant difference) test was carried out to test which groups mean value differ from which. For all comparisons, P-values of < 0.05 were considered statistically significant.

Results

Physical characteristics:

30, 33 and 37 individuals were involved in control, ND and TH respectively. No significant variations in subjects' ages and BMI were noted between groups. Relative to control group, significant elevation in cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol were obtained in hyperlipidemia groups (Table 1).

Table 1: Physical characteristics and plasma lipid profile in control and hyperlipidemia groups ($\bar{x} \pm SE$)

Fatty acid	Group		
	Control n=30	ND N=33	TH n=37
Age (years)	48.00 \pm 0.534 ^a	48.46 \pm 1.671 ^a	47.03 \pm 1.758 ^a
BMI (kg/m ²)	23.56 \pm 0.296 ^a	23.37 \pm .177 ^a	23.71 \pm 0.368 ^a
Women / Men ratio	22/8	19/18	21/12
Cholesterol (mmol/l)	3.67 \pm 0.082 ^A	5.93 \pm 0.164 ^B	5.83 \pm 0.188 ^B
Triglycerides (mmol/l)	1.29 \pm 0.074 ^A	3.27 \pm 0.239 ^B	3.19 \pm 0.195 ^B
LDL-C (mmol/l)	1.90 \pm 0.104 ^A	3.69 \pm 0.116 ^B	3.60 \pm 0.158 ^B
HDL-C (mmol/l)	1.32 \pm 0.047 ^a	1.14 \pm 0.059 ^a	1.13 \pm 0.063 ^a

ND: Newly diagnosed hyperlipidemia, TH: Treated hyperlipidemia

BMI: Body mass index

LDL-C: Low density lipoprotein, HDL-C: High density lipoprotein

In the same raw, same letters indicate non-significant P value ($P > 0.05$), while different capital letters indicate high significant P value ($P < 0.001$).

Saturated fatty acids:

In all groups, the most abundant saturated fatty acids in RBC membrane were palmitic and stearic acids, representing 55.28 % and 42.82 % from total SFAs in control group, 56.70 % and 41.26 % in ND and 57.98 % and 40.02 % in TH respectively.

Significant differences between control, newly diagnosed and treated hyperlipidemia groups were noted for saturated fatty acids with 12, 14, 15, 16, 17 and 18 carbon atoms in membrane of RBC, although saturated fatty acids C12:0 and C20:0 did not show significant variations between groups (Table 2). Detectable values for arachidic acid (C20:0) were only obtained in 12, 18, and 24 cases in control, ND and TH respectively, the rest of participants (18, 15 and 13 cases in C, ND and TH respectively) were presented with non-detectable values. Therefore, the mean values concerning this FA were calculated from detectable values only. No significant change in individual SFAs were obtained between ND and TH hyperlipidemia (Table 2). Results in Table 4 revealed significantly elevated mean for SFA in hyperlipidemia groups compared to healthy control subjects.

Table 2: Saturated fatty acids ($\mu\text{g/ml}$) in RBC membrane for control and hyperlipidemia groups ($\bar{x} \pm SE$)

Group	Control n=30	ND n=33	TH n=37
Fatty acid			
Lauric acid	0.24 \pm 0.024 ^a	0.21 \pm 0.014 ^a	0.23 \pm 0.012 ^a
C12:0	0.17 (0.06)	0.11 (0.04)	0.13 (0.05)
% from total SFA*			
Myristic acid	0.80 \pm 0.056 ^A	1.41 \pm 0.126 ^B	1.40 \pm 0.079 ^B
C14:0	0.58 (0.21)	0.75 (0.26)	0.80 (0.31)
% from total SFA*			
Pentadecanoic acid	0.35 \pm 0.025 ^A	0.49 \pm 0.037 ^B	0.44 \pm 0.022 ^B
C15:0	0.25 (0.10)	0.26 (0.09)	0.25 (0.10)
% from total SFA*			
Palmitic acid	76.11 \pm 4.250 ^A	106.09 \pm 6.319 ^B	101.95 \pm 4.721 ^B
C16:0	55.28 (19.94)	56.70 (19.22)	57.98 (22.25)
% from total SFA*			
Heptadecanoic acid	0.73 \pm 0.051 ^A	1.09 \pm 0.078 ^B	0.96 \pm 0.044 ^B
C17:0	0.53 (0.19)	0.58 (0.20)	0.55 (0.21)
% from total SFA*			
Stearic acid	58.95 \pm 3.714 ^A	77.21 \pm 4.634 ^{B,a}	70.36 \pm 3.183 ^{A,a}
C18:0	42.82 (15.44)	41.26 (13.99)	40.02 (15.36)
% from total SFA*			
Arachidic acid	0.49 \pm 0.055 ^a	0.61 \pm 0.045 ^a	0.49 \pm 0.037 ^a
C20:0**	0.36 (0.13)	0.32 (0.11)	0.28 (0.11)
% from total SFA*			

*SFA: Saturated fatty acid, ND: Newly diagnosed hyperlipidemia, TH: Treated hyperlipidemia

* Values outside parenthesis indicate % from total SFA, while values inside parenthesis indicate % from total Fatty acid

**The mean values for arachidic acid were calculated for detectable cases (12, 18 and 24 in control, ND and TH respectively)

Unsaturated fatty acids

All extracted unsaturated fatty acids from RBC membrane showed significant variations between all the studied groups except linoleic acids and cis-eicosatrienoic acid. In control and hyperlipidemia groups, linoleic acid (C18:2, n-6) and docosahexaenoic acid (C22:6, n-3) represented the highest ratio from total USFAs, followed by elaidic (C18:1, n-9t) and oleic acid (C18:1, n-9c). No statistical variations between the two hyperlipidemia groups for the individual USFAs with the exception of cis-eicosenoic acid (C20:1, n-9). Wide variations in the individual data of C22:6, n-3 were detected in control and hyperlipidemia groups, the mean values were determined

from only 30, 28 and 16 cases in control, ND and TH respectively. The excluded cases (5 and 21 cases in ND and TH respectively) were presented with individual values below 1.0 µg/ml for statistical analysis (Table 3). Elevated levels of monounsaturated fatty acids, polyunsaturated fatty acids, n-6 PUFAs and n-3PUFAs among patients with hyperlipidemia compared to healthy control were noted. Results also indicated decreased saturation index (SI) in RBC membrane in ND and TH compared to healthy volunteers. Although the mean values of n-6 PUFAs in ND and TH were increased relative to their matched values in control, however, the percent of n-6 PUFA from total FAs was decreased. The mean values of n-3 PUFAs percentage were significantly elevated in ND, but not in TH, compared to control groups. No significant variation of n-3/n-6 PUFAs ratio between control and hyperlipidemia groups was obtained (Table 4).

Table 3: Unsaturated fatty acids (µg/ml) in RBC membrane for control and hyperlipidemia groups ($\bar{x} \pm SE$)

Group	Control	ND	TH
Fatty acid	n=30	n=33	n=37
Myristoleic acid C14:1	0.04 ± 0.006 ^A	0.06 ± 0.007 ^{A,a}	0.08 ± 0.009 ^{B,a}
% from total MUFA*	0.07 (0.01)	0.06 (0.01)	0.08 (0.02)
Palmitoleic acid C16:1	1.61 ± 0.184 ^A	2.91 ± 0.280 ^{A,a}	3.61 ± 0.357 ^{B,a}
% from total MUFA*	2.88 (0.42)	3.02 (0.53)	3.78 (0.79)
cis-10-Heptadecanoic acid C17:1	0.34 ± 0.025 ^A	0.72 ± 0.068 ^B	0.82 ± 0.069 ^B
% from total MUFA*	0.61 (0.09)	0.75 (0.13)	0.86 (0.18)
Oleic acid C18:1, n-9c	28.36 ± 3.026 ^A	42.07 ± 3.262 ^{B,a}	38.01 ± 2.494 ^{A,a}
% from total MUFA*	50.75 (7.43)	43.62 (7.62)	39.75 (8.30)
Elaidic acid C18:1, n-9t	25.15 ± 4.106 ^A	49.75 ± 4.196 ^B	52.39 ± 3.711 ^B
% from total MUFA*	45.01 (6.59)	51.58 (9.01)	54.79 (11.44)
gamma-linolenic acid C18:3, n-6	0.23 ± 0.035 ^A	0.64 ± 0.095 ^B	0.60 ± 0.050 ^B
% from total MUFA*	0.12 (0.06)	0.24 (0.12)	0.32 (0.13)
cis-11-eicosenoic acid C20:1, n-9	0.38 ± 0.050 ^A	0.94 ± 0.084 ^B	0.72 ± 0.047 ^C
% from total MUFA*	0.68 (0.09)	0.97 (0.17)	0.75 (0.16)
Linoleic acid C18:2, n-6	83.97 ± 8.334 ^A	101.89 ± 7.359 ^A	88.70 ± 4.504 ^A
% from total PUFA**	44.62 (21.99)	37.97 (18.46)	47.51 (19.36)
cis-11,14-eicosatrienoic acid C20:2, n-6	0.70 ± 0.079 ^A	0.52 ± 0.110 ^A	0.71 ± 0.086 ^A
% from total PUFA**	0.37 (0.18)	0.19 (0.09)	0.38 (0.15)
cis-11,14,17 eicosatrienoic acid C20:3,n-3	0.06 ± 0.007 ^A	6.59 ± 1.230 ^B	5.53 ± 0.802 ^B
% from total PUFA**	0.03 (0.01)	2.46 (1.19)	2.96 (1.21)
Arachidonic acid C20:4, n-6	17.21 ± 1.688 ^A	26.45 ± 3.798 ^B	14.86 ± 1.785 ^C
% from total PUFA**	9.14 (4.51)	9.86 (4.79)	7.96 (3.24)
cis-4,7,10,13,16,1 docosahexaenoic acid C22:6,n-3 ***	86.04 ± 8.44 ^A	132.24 ± 18.989 ^{A,A}	76.28 ± 13.975 ^{A,B}
% from total PUFA**	45.71 (22.54)	49.28 (23.96)	40.86 (16.65)

In the same raw, same letters indicate non-significant P value ($P > 0.05$), while different capital letters indicate high significant P value ($P < 0.001$).

MUFA: Monounsaturated fatty acid, PUFA: Polyunsaturated fatty acid, ND: Newly diagnosed hyperlipidemia, TH: Treated hyperlipidemia.

*Values outside parenthesis indicate % from total MUFA

**Values outside parenthesis indicate % from PUFA, while values inside parenthesis indicate % from total Fatty acid.

*** The mean values for docosahexaenoic acid were calculated for detectable cases (12, 18 and 24 in control, ND and TH respectively).

In the same raw, same letters indicate non-significant P value ($P > 0.05$), while different capital letters indicate high significant P value ($P < 0.001$).

Table 4: Contents (µg/ml) of RBCs membrane SFAs, MUFAs, PUFAs, n-3PUFAs, n-6PUFAs, SI and n-3PUFA/n-6 PUFA in control and hyperlipidemia groups

Group	Control	ND	TH
Fatty acid	n=30	n=33	n=37
SFA	135.46 ± 7.561 ^A	225.18 ± 15.000 ^B	207.52 ± 12.204 ^B
% from total FA	35.96	38.85	39.17
MUFA	52.40 ± 28.14 ^A	96.04 ± 6.074 ^B	95.21 ± 6.146 ^B
% from total FA	13.91	16.57	17.97
PUFA	188.85 ± 15.583 ^A	258.42 ± 20.211 ^{B,a}	227.01 ± 11.275 ^{A,a}
% from total FA	50.13	44.58	42.85
n-6 PUFA	172.74 ± 13.87 ^A	228.78 ± 16.176 ^{B,a}	208.51 ± 10.626 ^{A,a}
% from total FA	45.85	39.47	39.36
n-3 PUFA	18.77 ± 1.720 ^A	32.78 ± 4.625 ^B	20.25 ± 1.652 ^A
% from total FA	4.98	5.66	3.82
n-3/n-6 PUFA	0.11 ± 0.005 ^A	0.14 ± 0.012 ^{A,a}	0.10 ± 0.007 ^{A,B}
SI	2.37 ± 0.118 ^A	1.94 ± 0.074 ^B	2.07 ± 0.076 ^B

ND: Newly diagnosed hyperlipidemia, TH: Treated hyperlipidemia

SFA: Saturated fatty acids = 12:0 + 14:0 + 15:0 + 16:0 + 17:0 + 18:0.

MUFA: Monounsaturated fatty acids = 14:1 + 16:1 + 17:1 + 18:1, n-9c + 18:1, n-9t + 20:1, n-9c.

UFAs: Polyunsaturated fatty acids = 18:2, n-6c + 20:2 + 18:3, n-6c + 20:3, n-3c + 20:4, n-6c + 22:6, n-3c.

n-6 PUFAs = 18:2, n-6c + 18:3, n-6c + 20:4, n-6c

n-3 PUFAs = 20:3, n-3c + 22:6, n-3c.

SI: Saturation index = C18:0 / C18:1, n-9c.

In the same raw, same letters indicate non-significant P value ($P > 0.05$), while different capital letters indicate high significant P value ($P < 0.001$).

Discussion

The present study demonstrated changes in plasma fatty acids in hyperlipidemia patients, either newly diagnosed (ND) or treated hyperlipidemia (TH), compared to control subjects. Almost all saturated and unsaturated fatty acids showed measurable increase in hyperlipidemia group than control one. Patients with hyperlipidemia had pronounced increased levels of total: SFAs, MUFAs, PUFAs, n-3PUFAs and n-6PUFAs than control volunteers. Saturation index (SI) was reduced in patients' groups compared to control healthy volunteers.

In the current study, hyperlipidemic patients had considerable changes in almost all estimated saturated fatty acids in RBC membrane. Elevated SFAs could be due to high intake of hazelnut, fat rich dairy products, fatty meats and sausages^[21-23]. Elevated mean values of membrane SFAs were due to increased levels of palmitic (C16:0) and stearic (C18:0) acids. From total SFAs, both palmitic and stearic acids represented 56.70% and 41.26% respectively in newly diagnosed hyperlipidemia, while in treated hyperlipidemia, palmitic acid represented 57.98% and stearic acid represented 40.2%. In control group, the percent of palmitic /SFAs and stearic /SFAs were 55.28% and

42.82% respectively. In control group, SFAs in RBC membrane represented 35.96% from total fatty acids, while in hyperlipidemia patients it represented 38.85% in ND and 39.17% in TH from total fatty acids. Our data are consistent with previous studies [6, 24] reported that both palmitic and stearic acids were the major contributing factors in SFAs of RBC membrane in patients with arterial blood pressure associated with dyslipidemia. Elevated stearic acid level was also observed in animal model kept on high fat diet for long term [25]. Saturated fatty acids are non-essential FA and are harmful if ingested excessively in food. They favor excess weight, insulin resistance [26] increased LDL-Cholesterol and are atherogenic [27]. Increased percent of SFA/PUFA were previously reported to be positively correlated with different diseases [4, 6, 28]. Increased SFA in RBC lead to decreased fluidity of the cell lipid bilayer, an activity of membrane bound enzymes and inhibition of binding the ligands with receptor [29, 30].

USFAs are the major fatty acids contributing to permeability, fluidity of the RBC membrane and also to the function of the membrane via receptors and membrane bond energy [31]. Although, higher mean values levels for USFA (MUFA and PUFA) were detected in hyperlipidemia subgroups, however their percent from total fatty acids were lower than the control. From total FA, USFA represented 61.3% in ND and 60.82% in TH compared to 64.04% in control. In our study, levels of MUFAs were higher in ND hyperlipidemia compared to healthy subjects. Same trend was also noted in TH patients compared to control volunteers. Non-essential MUFAs and namely its main component oleic acid have a beneficial effect upon cholesterol metabolism and a protective role against cardiovascular diseases [32]. Both oleic (C18:1, n-9c) and elaidic (C18:1, n-9t) acids were the major contributors in RBC membrane MUFAs in all groups. Significantly elevated levels of both FAs were observed in hyperlipidemia patients compared to healthy subjects. Novgorodtseva et al. [33] indicated that all patients with arterial hypertension associated with dyslipidemia had measurable increased erythrocyte membrane MUFA C18:1n9 (oleic acid). Decreased percent of oleic acid/ MUFA was noted in control (50.75%) than newly diagnosed (43.62%) and treated hyperlipidemia (39.75%). However opposite trend was obtained for elaidic acid, where higher percent of elaidic /MUFA was detected in ND and TH patients compared to control subjects.

The high levels of MUFAs in hyperlipidemia might be primarily due to increased consumption of olive oil [34, 35]. A high dietary MUFAs contents is probably one determinant, but not the major one, of erythrocyte membrane MUFAs [36-38] which are synthesized in the body [39, 40]. High level of MUFAs especially oleic acid and elaidic acid in dyslipidemia, either newly diagnosed or treated, and low saturation index may also be related to other factor than diet. Most oleic acid in mammalian tissue is derived from diet or saturated stearic acid residue [39, 41, 42]. The later was the second abundant SFA in RBC membrane in our study. The conversion is catalyzed by $\Delta 9$ -desaturase enzyme, which also regulates the transformation of the other common SFAs (myristic and palmitic) to their corresponding monounsaturated forms, myristoleic and palmitoleic [4]. In our study, all these FAs were elevated in RBC membrane of hyperlipidemia patients than control subjects. This finding was supported by the obtained significant positive correlations, in

RBC membrane, between stearic and oleic acids in all studied groups, as well as between myristic and its corresponding fatty acid myristoleic and between palmitic and palmitoleic acids. Their significant correlations might indicate that increased dietary SFAs might lead to elevated membrane SFAs which intern will lead to higher values of MUFAs in ND and TH patients. Therefore, the observed higher MUFAs mean values in hyperlipidemia compared to control may be mostly due to increased $\Delta 9$ -desaturase activity. Several factors are known to exert an important effect on $\Delta 9$ -desaturase activity. The fat contents of the diet have an important effect on the enzyme activity [43], which might explain the higher concentration of MUFAs in dyslipidemia compared to control subjects, since this group of patients was presented with significantly elevated plasma cholesterol and triglycerides, indicating their quality of diet. A high cholesterol diet was also reported to increase $\Delta 9$ -desaturase activity resulting in increased monounsaturated of the membrane fatty acids in rat liver to partially compensate for the rigid zing effect of cholesterol incorporation in the membrane [40]. Additionally, $\Delta 9$ -desaturase activity was found to be activated by carbohydrate [44] and insulin [34, 45] which might point out to the possible relationships between increased dietary carbohydrate and elevated MUFAs.

In this work, RBC membrane polyunsaturated fatty acids represented higher percentage from total FAs in all groups. In hyperlipidemia patients, the percent of PUFAs from total FAs was decreased in ND (44.58%) and in TH (42.85%) compared to control group value (50.13%). Polyunsaturated fatty acids are designated as essential for good health, as their metabolic precursors cannot be synthesized in the body and must be ingested by food intake [46]. PUFAs have important effects on the structure and physical properties of localized membrane domains. They modulate enzyme activities, carriers and membrane receptors. PUFAs are involved in eicosanoid (prostaglandins, prostacyclins, thromboxanes, leukotrienes) production, signal transduction, and the activation of nuclear transcription factors [47]. Parent essential FAs contributors in PUFAs are linoleic (C18:2, n-6c) and linolenic (C18:3, n-3c) acids. It is well established that α -linolenic acid content of erythrocyte membrane is very low and is largely unrelated to dietary intake [48, 49]. Researchers [30] had indicated that the desaturation and elongation of essential fatty acids, linoleic and linolenic, results in the formation of PUFAs of n-6 and n-3 series. In our study, significant positive correlations were detected between linoleic acid and most PUFA of n-6 and n-3 series in hyperlipidemia subjects. Other contributors in PUFA were arachidonic acid (C20:4, n-6) and C22:6, n-3. It is worth to point out to the lack of significant difference between hyperlipidemia and control groups for linoleic acid levels. On the other hand, significant elevation was obtained in plasma linoleic acid in hyperlipidemia patients relative to control group. Arachidonic acid was reported to be higher in arterial hypertension patients with dyslipidemia compared to healthy group [33, 50]. Elevated erythrocyte membrane C20:4, n6 was also found to be increased in animals fed high fat diet for a long period [25]. Linoleic acid is an essential fatty acid [51], after being absorbed, it undergoes desaturation/saturation and chain elongation/shortening reactions, producing n-6 fatty acids, arachidonic acid [52, 53]. In our study, significantly elevated

arachidonic acid mean value was noted in newly diagnosed hyperlipidemia compared to control. We also observed decreased linoleic/arachidonic ratio in ND hyperlipidemia compared to control group (3.9 in ND and 4.9 in control). In addition to the obtained significant positive correlation between membrane linoleic and membrane arachidonic acids. This finding might suggest that the conversion of linoleic to arachidonic acid could be active in ND hyperlipidemia patient, which properly indicate higher activity of elongase or of $\Delta 9$ desaturase for the formation of arachidonic from linoleic acid. Therefore, the increased concentration of arachidonic acid and other n-6 PUFAs observed in ND hyperlipidemia may indicate increased transformation of linoleic acid to arachidonic acid and to other n-6PUFA, or increased dietary intake. Our study revealed significant reduction (although it was borderline significant, $P = 0.05$) in the mean value of membrane arachidonic acid in TH compared to ND subgroup. On the other hand, the increased linoleic/ arachidonic ration in treated hyperlipidemia (5.9) relative to control (4.9) raised the possibility that diversion of linoleic acid metabolism away from arachidonic acid (and hence from arachidonic acid - derived prostaglandins) might be a protective step in hyperlipidemia patients under treatment^[54]. Arachidonic acid is a predecessor of synthesis of anti-inflammatory leukotrienes and thromboxanes with their strong aggregation and vasoconstriction properties^[55, 56]. It is worth mentioning that some n-6PUFAs, but not arachidonic acid, in TH subgroup could be also due to decreased dietary intake.

In our study, the observed increase in the percent of membrane SFAs with simultaneous decrease in PUFA percent from total fatty acids in hyperlipidemia compared to control values may be an evidence for transport pathology with a predominance of cells passive fatty acids absorption. The integral parameters of the cells impaired absorption both of SFAs and of PUFAs are low levels of HDL-C and high levels of cholesterol and triglycerides in plasma^[57, 58].

The saturation index (SI) in erythrocyte membrane is the ratio of stearic to oleic acid. The SI is an indicator of membrane fluidity; its reciprocal is considered to be an index of the activity of the rate-limiting enzyme delta 9-desaturase that transforms the SFAs palmitic and stearic acids, respectively, into the MUFAs palmitoleic and oleic acid^[39]. Our results indicated that hyperlipidemia group was associated with decreased saturation index. This result is in agreement with previous study^[25]. The observed elevated levels of oleic acid and low SI in hyperlipidemic patients may reflect poor PUFAs in diet^[4].

It was concluded from the present study that patients with hyperlipidemia, either ND or TH, had pronounced elevation in almost all FAs in RBC membrane. The percentage of SFAs and MUFAs from total FAs were increased while the percentage of PUFAs was decreased in hyperlipidemia. Increased dietary SFAs might lead to elevated membrane SFAs which in turn will lead to higher levels of MUFAs in ND and TH patients. Saturation index of RBC membrane, was decreased in patients' groups compared to control. Increased dietary intake and alterations in the metabolism of FAs may be responsible for the observed changes.

From the present study, the percent of SFAs, MUFAs and PUFAs from total FAs in RBC membrane should be

determined, since this data will give information about the membrane fluidity and viscosity, which consequently indicate RBCs functions. Determination of lipid profiles requires fasting for at least 12h. Some patients are unable to fast for long time; therefore, analysis of RBC membrane fatty acids might be useful in this case. Balanced dietary fat with balanced intake of both n-3 and n-6 polyunsaturated fatty acid is essential to maintain normal plasma lipids and for better health. Analysis of RBC fatty acids during routine follow up of hyperlipidemia patients is highly recommended since it might provide information on the dietary fat intake for long period.

Acknowledgment

Thanks and appreciations are directed to King Abdulaziz City for Science and Technology for financial support) TA-10-231) to the project of the research.

References

1. Gabreanu GR, Angelescu S. Erythrocyte membrane in type 2 diabetes mellitus. *Discoveries* 2016; 4(2): 1-12
2. Tsuda K, Kimura K, Nishio I, Masuyama Y. Nitric oxide improves membrane fluidity of erythrocytes in essential hypertension: an electron paramagnetic resonance investigation. *Biochem Biophys Res Comm* 2000; 275: 946-954.
3. Tsuda K, Shimamoto YK, Kimura K, Nishio I. Nitric oxide is a determinant of membrane fluidity of erythrocytes in postmenopausal woman: An electron paramagnetic resonance investigation. *Am J Hyper* 2003; 16: 244-248.
4. Pala V, Krogh V, Muti P, Chajes V, Riboli E, Micheli A, Saadatian M, Sieri S, Berrino F. Erythrocyte Membrane Fatty Acids and Subsequent Breast Cancer: A Prospective Italian Study. *J Natl Cancer Inst* 2001; 93:1088-1095.
5. Kuriki K, Wakai K, Hirose K, Matsuo K, Ito H, Suzuki T, et al. Risk of Colorectal Cancer is Linked to Erythrocyte Intakes of Fish, Fat, and Fatty Acids Compositions of Fatty Acids as Biomarkers for Dietary, *Cancer Epidemiol Biomarkers* 2006; 15:1791-1798.
6. Kuliavienė I, Gulbinas A, Cremers J, Pundzius J, Kupcinskis L, Dambrauskas Z, Jansen E. Fatty acids of erythrocyte membrane in acute pancreatitis patients, *World J Gastroenterol* 2013; 19(34): 5678-5684.
7. Chapman D. Recent physical studies of phospholipids and natural membranes. In *Biological Membranes. Physical Fact and Function*. D. Chapman, editor. Academic Press, London 1968; 125-202.
8. Cooper R A, Durocher R J, Leslie M H. Decreased fluidity of red cell membrane lipids in abetalipoproteinemia. *J. Clin. Invest* 1977; 60: 115-121.
9. Shinitzky M, Inbar M. Microviscosity parameters and protein mobility in biological membranes. *Biochim. Biophys. Acta* 1976; 433:133-149.
10. Borochoff H, Zahler P, Wilbrandt W, Shinitzky M. The effect of phosphatidylcholine to sphingomyelin mole ratio on the dynamic properties of sheep erythrocyte membrane. *Biochim. Biophys. Acta* 1977; 470: 382-388.

11. Cooper RA. Abnormalities of cell-membrane fluidity in the pathogenesis of disease. *N Engl J Med* 1977; 297: 371-377.
12. Jahnig F. Structural order of lipids and proteins in membranes: evaluation of fluorescence anisotropy data. *Proc. Natl. Acad. Sci* 1979;76: 6361-6365.
13. Chapman D, Gómez-Fernández J C, Goffi FM. Intrinsic protein-lipid interactions. Physical and biochemical evidence. *FEBS Lett* 1979; 98: 211-223.
14. Kanakaraj P, Singh M. Influence of Hypercholesterolemia on morphological and rheological characteristics of erythrocytes. *Atherosclerosis* 1989; 76: 209-18.
15. Unruh D, Srinivasan R, Benson T, Haigh S, Coyle D, Batra N, et al. Red Blood Cell Dysfunction Induced by High-Fat Diet: Potential Implications for Obesity-Related Atherosclerosis. *Circulation*. 2015;132(20):1898-908.
16. Sparrow RL. Red blood cell components: time to revisit the sources of variability. *Blood Transfus* 2017; 15(2): 116-125.
17. Mancía G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the Management of Arterial Hypertension: the task force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and European Society of Cardiology (ESC). *J Hypertens* 2007; 25:1105-1187
18. Folch J, Lees M, Sloane Stanley GH. A simple Method for the isolation and purification of total lipids from Animal tissues. *J Biol Chem* 1957; 226: 497-509.
19. Rose G, Oklander M. Improved procedure for the extraction of lipids from human erythrocytes. *J Lipid Res* 1965; 6:428-431.
20. Khedr A, Abd-Elaaty M, Hegazy A, Kamal A. Profiling of plasma esterified fatty acids contents in dengue fever patients applying optimized GC MS method. *Metabolomics* 2014; 4 (2): 154.
21. Deon V, Del Bo' C, Guaraldi F, Abello F, Belviso S, Porrini M, Riso P, Guardamagna O. Effect of hazelnut on serum lipid profile and fatty acid composition of erythrocyte phospholipids in children and adolescents with primary hyperlipidemia: A randomized controlled trial. *Clin Nutr* 2017; S0261-5614(17)30196-6.
22. Keys A. Coronary heart disease-the global picture. *Atherosclerosis* 1975; 22: 149-92.
23. Pietinen P, Dougherty R, Mutanen M, et al. Dietary intervention study among 30 free-living families in Finland. *J Am Diet Assoc* 1984; 84:313-318.
24. Ristic-Medic D, Suzic S, Vucic V, Takic M, et al. Serum and erythrocyte membrane phospholipids fatty acid composition in hyperlipidemia: effects of dietary intervention and combined diet and fibrate therapy. *Gen Physiol Biophys* 2009; 28:190-199.
25. Novgorodtseva TP, Karaman YK, Zhukova NV. The effect of high fat food on erythrocyte phospholipids, fatty acids composition and glutathione redox-system of rats with alimentary dyslipidemia. *Health* 2010; 2:45-50.
26. Folsom AR, Ma J, Aggovern PG, Eckfeldt JH. Relation between plasma phospholipid saturation fatty acids and hyperinsulinemia. *Metabolism* 1996; 25: 223-228.
27. Ma J, Folsom R, Lewis L, Eckfeldt H. Relation of plasma phospholipids and cholesterol ester fatty acid composition to carotid artery intima-media thickness: the atherosclerosis risk in communities (ARIC) study. *Am J Clin Nutr* 1997; 65: 551-559.
28. Pandey M, Khatri AK, Dubey SS, Gautam A, Shukla VK. Erythrocyte membrane stearic to oleic acid ratio in carcinoma of the gallbladder: a preliminary study. *World Journal of Surgical Oncology* 2003; 1.
29. Endakova EA, Novgorodtseva TP, Svetashev VI. Modification of blood fatty acids composition in case of cardiovascular diseases. *Vladivostok: Dalnauka* 2002; 296.
30. Potyomkin VV, Troitskaja SJ, Maksina AG. Metabolic indicators and struktura membranes erythrocytes at obesity and a metabolic syndrome at women. *Russian Medical Journal* 2006; 1: 35-38.
31. Popp-Snijders C, Schouten JA, van Blitterswijk WJ, van der Veen EA. Changes in membrane lipid composition of human erythrocyte after dietary supplementation of (n-3) polyunsaturated fatty acids. Maintenance of membrane fluidity. *Biochim. Biophys* 1986; 854: 31-37
32. De Lacruz JP, Villalobos MA, Carmona JA, Romero M, Agreda JM, de Lacuesta F. Antithrombotic potential of olive oil administration in rabbits with elevated cholesterol. *Thromb Res* 2000; 100: 305-315.
33. Novgorodtseva TP, Karaman YK, Gvozdenko TA, Antonyuk MV, Knysheva VV. Fatty acids composition of erythrocytes in arterial hypertension associated with dyslipidemia. *Health* 2013; 5: 73-77.
34. Menotti A, Conti S, Giampoli S, Mariotti S, Signoretti A. Coronary risk factors predicting coronary and other causes of death in fifteen years. *Acta Cardiol* 1980; 35: 107-120.
35. Ferro-Luzzi A, Strazzullo P, Scaccini C, Siani A, Sette S, Mariani MA, et al. Changing the Mediterranean diet: effects on blood lipids. *Am J Clin Nutr* 1984; 40:1027-1037.
36. Dougherty, R.M., Galli, C., Ferro-Luzzi, A. and Iacono, J.M. Lipid and phospholipid fatty acid composition of plasma, red blood cells, and platelets and how they are affected by dietary lipids: a study of normal subjects from Italy, Finland, and the USA. *Am J Clin Nutr* 1987; 45:443-455.
37. Corrocher R, Pagnan A, Ambrosio GB, Ferrari S, Olivieri O, Guarini P, et al. Effects induced by olive oil-rich diet on erythrocytes membrane lipids and sodium-potassium transports in postmenopausal hypertensive women. *J Endocrinol Invest* 1992; 15:369-376.
38. Kohlmeier L. Biomarkers of fatty acid exposure and breast cancer risk. *Am J Clin Nutr* 1997; 66 (6):1548S-6S.
39. Fernandez C, Schuhmann K, Herzog R, Fielding B, Frayn K, Shevchenko A, et al. Altered desaturation and elongation of fatty acids in hormone-sensitive lipase null mice. *PLoS One* 2011;6(6):e21603.
40. Brenner RR. Endocrine control of fatty acid desaturation. *Biochem Soc Trans* 1990; 18:773-775.
41. Zoeller RA, Wood R. The importance of the stearyl-CoA desaturase system in octadecenoate metabolism in

- the Morris hepatoma 7288C. *BiochimBiophysActa* 1985; 845:380–8.
42. Polo-Hernández E, De Castro F, García-García AG, Taberero A, Medina JM. Oleic acid synthesized in the periventricular zone promotes axonogenesis in the striatum during brain development. *J Neurochem* 2010; 1756-1766.
 43. Waters KM, Ntambi JM. Polyunsaturated fatty acids inhibit hepatic stearoyl-CoA desaturase-1 gene in diabetic mice. *Lipids* 1996; 31: S33–S36.
 44. Berra B, Rapelli S. Utilization of dietary fats with particular reference to olive oil: biochemical and nutritional aspects. *La RivistadelleSostanze Grasse* 1987; 64:317–324.
 45. Ntambi JM, Sessler AM, Takova T. A model cell line to study regulation of stearoyl-CoA desaturase gene 1 expression by insulin and polyunsaturated fatty acids. *BiochemBiophys Res Commun* 1996; 220:990-995.
 46. Abedi E, SahariMA. Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. *Food SciNutr* 2014; 2(5): 443–463.
 47. Spector A. Essentiality of fatty acids. *Lipids* 1999; 34: S1–S3.
 48. Brox JH, Killie J, Gunnes S, Nordoy A. The effect of cod liver oil and corn oil on platelets and vessel wall in man. *ThrombHaemost (Stuttgart)* 1981; 46:604-11.
 49. Goodnight SH, Harris ES, Connor WE, Illingworth DR. Polyunsaturated fatty acids, hyperlipidemia and thrombosis. *Atherosclerosis* 1982; 2: 87-113.
 50. Novgorodtseva TP, Kantur TA, Karaman YK, Antonyuk MV, Zhukova NV. Modification of fatty acids composition in erythrocytes lipids in arterial hypertension associated with dyslipidemia. *Lipids* 2011; 10:18.
 51. Halliwell B, Gutteridge JMC. *Free Radicals in Biology and Medicine*, 3rd Edition, Oxford University Press 1999.
 52. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. *Am J ClinNutr* 2000; 71:343-348.
 53. Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S. Arachidonic acid and colorectal carcinogenesis. *Mol Cell Biochem* 2003; 253:141-149.
 54. Chapkin R S, Hubbard N E, Buckman D K, Erickson K L. Linoleic acid metabolism in metastatic and nonmetastatic murine mammary tumor cells. *Cancer Res* 1989; 49:4724–4728.
 55. Zhou L, Nilsson A. Sources of eicosanoid pre-cursor fatty acid pools in tissues. *J Lipid Res* 2001; 42:1521-1542.
 56. Novgorodtseva TP, KaramanYuK, Antoniuk MV, Zhukova NV. The role of free and esterified fatty acids in pathogenesis of metabolic syndrome. *Klin Med* 2009; 87(5): 33-7.
 57. Calder PC, Yaqoob P. Lipid rafts-composition, characterization and controversies. *J Nutr* 2007; 137:545-7.
 58. Norris PC, Dennis EA. Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. *P Natl AcadSciUSA* 2012; 12:8517-22.